Influence of the definition of "metabolically healthy obesity" on the progression of coronary artery calcification

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Yoon, Ji Won ^a,b   Jung, Chan Hyeon ^b   Kim, Min Kyung ^a,b   Park, Hyo Eun ^a,b   Park, Kyong Soo ^b   Jang, Hak Chul ^b,c   Moon, Min Kyong ^b,d   Choi, Su Yeon ^a,b   Koo, Bo Kyung ^b,d  

^a Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METABOLICALLY HEALTHY OBESITY; OBESITY; PHENOTYPE; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ANTHROPOMETRY; BLOOD; BLOOD PRESSURE; CALCINOSIS; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DISEASE COURSE; INCIDENCE; METABOLICALLY BENIGN OBESITY; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PATHOPHYSIOLOGY; RISK;

BIOLOGICAL MARKER; CALCIUM; LIPID;

ADULT; ANTHROPOMETRY; BIOMARKERS; BLOOD PRESSURE; CALCINOSIS; CALCIUM; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; OBESITY, METABOLICALLY BENIGN; PHENOTYPE; RETROSPECTIVE STUDIES; RISK;

EID: 85020187484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178741     Document Type: Article

References (44)

1. Bastien M, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014; 56(4): 369-381. https://doi.org/10.1016/j.pcad. 2013.10.016
2. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168(15): 1617-1624. https://doi.org/10.1001/archinte.168.15.1617
3. Stefan N, Haring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 2013; 1(2): 152-162. https://doi.org/10.1016/S2213-8587(13)70062-7
4. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168(15): 1609-1616. https://doi.org/10.1001/archinte.168.15.1609
5. Karelis AD, Rabasa-Lhoret R. Obesity: Can inflammatory status define metabolic health? Nat Rev Endocrinol 2013; 9(12): 694-695. https://doi.org/10.1038/nrendo.2013.198
6. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, Barletta A. From chronic overnutrition to insulin resistance: The role of fat-storing capacity and inflammation. Nutr Metab Cardiovasc Dis 2009; 19(2): 146-152. https://doi.org/10.1016/j.numecd.2008.10.010
7. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-Associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117(9): 2621-2637. https://doi.org/10.1172/JCI31021
8. Kusminski CM, Holland WL, Sun K, Park J, Spurgin SB, Lin Y, et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med 2012; 18(10): 1539-1549. https://doi.org/10.1038/nm.2899
9. Herman MA, Peroni OD, Villoria J, Schon MR, Abumrad NA, Bluher M, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012; 484(7394): 333-338. https://doi.org/10.1038/nature10986
10. Eshtiaghi R, Keihani S, Hosseinpanah F, Barzin M, Azizi F. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: The Tehran Lipid and Glucose Study. Int J Obes (Lond) 2014.
11. Arnlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-Aged men. Diabetes Care 2011; 34(1): 61-65. https://doi.org/10.2337/dc10-0955
12. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91(8): 2906-2912. https://doi.org/10.1210/jc.2006-0594
13. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97(7): 2482-2488. https://doi.org/10.1210/jc.2011-3475
14. Song Y, Manson JE, Meigs JB, Ridker PM, Buring JE, Liu S. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol 2007; 100(11): 1654-1658. https://doi.org/10.1016/j.amjcard.2007.06.073
15. El Khoudary SR, Shin C, Masaki K, Miura K, Budoff M, Edmundowicz D, et al. Ectopic cardiovascular fat in middle-Aged men: effects of race/ethnicity, overall and central adiposity. The ERA JUMP study. Int J Obes (Lond) 2014.
16. Simons DB, Schwartz RS, Edwards WD, Sheedy PF, Breen JF, Rumberger JA. Noninvasive definition of anatomic coronary artery disease by ultrafast computed tomographic scanning: A quantitative pathologic comparison study. J Am Coll Cardiol 1992; 20(5): 1118-1126.
17. Bonow RO. Clinical practice. Should coronary calcium screening be used in cardiovascular prevention strategies? N Engl J Med 2009; 361(10): 990-997. https://doi.org/10.1056/NEJMcp0902177
18. Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol 2003; 92(7): 827-829.
19. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004; 24(7): 1272-1277. https://doi.org/10.1161/01.ATV.0000127024.40516.ef
20. McEvoy JW, Blaha MJ, Defilippis AP, Budoff MJ, Nasir K, Blumenthal RS, et al. Coronary artery calcium progression: An important clinical measurement? A review of published reports. J Am Coll Cardiol 2010; 56(20): 1613-1622. https://doi.org/10.1016/j.jacc.2010.06.038
21. Budoff MJ, Hokanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, et al. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging 2010; 3(12): 1229-1236. https://doi.org/10.1016/j.jcmg.2010.08.018
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-419.
23. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. 2000.
24. Jung CH, Lee MJ, Kang YM, Jang JE, Leem J, Hwang JY, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: The role of systemic inflammation. J Clin Endocrinol Metab 2015; 100(3): 934-941. https://doi.org/10.1210/jc.2014-3885
25. Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, et al. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J Clin Endocrinol Metab 2014; 99(8): 2952-2960. https://doi.org/10.1210/jc.2013-4427
26. Hinnouho GM, Czernichow S, Dugravot A, Nabi H, Brunner EJ, Kivimaki M, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: The Whitehall II cohort study. Eur Heart J 2015; 36(9): 551-559. https://doi.org/10.1093/eurheartj/ehu123
27. Eshtiaghi R, Keihani S, Hosseinpanah F, Barzin M, Azizi F. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: The Tehran Lipid and Glucose Study. Int J Obes (Lond) 2015; 39(3): 514-519.
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-3421.
29. Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: A cohort study. Diabetes Care 2013; 36(8): 2388-2394. https://doi.org/10.2337/dc12-1971
30. Heianza Y, Kato K, Kodama S, Suzuki A, Tanaka S, Hanyu O, et al. Stability and changes in metabolically healthy overweight or obesity and risk of future diabetes: Niigata wellness study. Obesity (Silver Spring) 2014; 22(11): 2420-2425.
31. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: A collaborative analysis of ten large cohort studies. BMC Endocr Disord 2014; 149.
32. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15(4): 827-832.
33. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-Term but high lifetime estimated risk for cardiovascular disease: The coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 2009; 119(3): 382-389. https://doi.org/10.1161/CIRCULATIONAHA.108. 800235
34. Aung K, Lorenzo C, Hinojosa MA, Haffner SM. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab 2014; 99(2): 462-468. https://doi.org/10.1210/jc.2013-2832
35. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-Analysis. Ann Intern Med 2013; 159(11): 758-769. https://doi.org/10.7326/0003-4819-159-11-201312030-00008
36. Harrington M, Gibson S, Cottrell RC. A review and meta-Analysis of the effect of weight loss on allcause mortality risk. Nutr Res Rev 2009; 22(1): 93-108. https://doi.org/10.1017/S0954422409990035
37. Chang Y, Kim BK, Yun KE, Cho J, Zhang Y, Rampal S, et al. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol 2014; 63(24): 2679-2686. https://doi.org/10.1016/j.jacc.2014.03. 042
38. Rhee EJ, Seo MH, Kim JD, Jeon WS, Park SE, Park CY, et al. Metabolic health is more closely associated with coronary artery calcification than obesity. PLoS One 2013; 8(9): e74564. https://doi.org/10. 1371/journal.pone.0074564
39. Jung CH, Lee MJ, Hwang JY, Jang JE, Leem J, Yang DH, et al. Association of metabolically healthy obesity with subclinical coronary atherosclerosis in a Korean population. Obesity (Silver Spring) 2014; 22(12): 2613-2620.
40. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. Assessment of coronary artery disease by cardiac computed tomography: A scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114(16): 1761-1791. https://doi.org/10.1161/CIRCULATIONAHA.106.178458
41. Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C, O'Shea DB. Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring) 2009; 17(3): 601-605.
42. Stefan N. Nonalcoholic Fatty Liver Disease and Coronary Artery Calcification. Clin Gastroenterol Hepatol 2016; 14(9): 1345-1346. https://doi.org/10.1016/j.cgh.2016.05.025
43. Stefan N, Fritsche A, Schick F, Haring HU. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 2016; 4(9): 789-798. https://doi.org/10.1016/S2213-8587(16) 00082-6
44. Volzke H, Alte D, Ittermann T, Schmidt CO, Rettig R, Mayerle J, et al. Subjects with sonographical hepatic steatosis should be excluded from studies to establish upper reference levels of serum transaminases. Liver Int 2011; 31(7): 985-993. https://doi.org/10.1111/j.1478-3231.2010.02371.x